LS60.F Clinical Laserthermia Systems AB (publ)
- Market cap
- EUR 5.44M
- P/E
- -
- P/B
- 1.23x
- ROE
- -81.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is LS60.F undervalued?
Graham numberThe Graham number of Clinical Laserthermia Systems AB (publ) cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Clinical Laserthermia Systems AB (publ) fundamental analysis
No fundamental analysis for Clinical Laserthermia Systems AB (publ) yet.
Clinical Laserthermia Systems AB (publ) stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Clinical Laserthermia Systems AB (publ)
Clinical Laserthermia Systems AB (publ) engages in the development of treatment tools for diseased tissue under the TRANBERG brand in Sweden. It offers TRANBERG, a thermal therapy system designed to deliver laser energy to heat the target tissue. The company also provides mobile laser unit, a controlling component with a wavelength of 1064 nanometers that provides multiple options to control treatment. In addition, it offers various gauge laser applicators and introducers, a…
Full company profileClinical Laserthermia Systems AB (publ) financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Clinical Laserthermia Systems AB (publ) annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 2.25M | 6.27M | 8.27M | 18.8M | 17.5M | 17.9M |
| Gross Profit | -3.63M | -2.79M | 3.00M | 10.4M | 10.9M | 11.0M |
| Operating Income | -60.6M | -67.4M | -65.5M | -54.2M | -28.9M | -46.4M |
| EBITDA | - | -57.8M | -68.4M | -44.8M | -39.4M | -36.3M |
| Net Income | -63.6M | -70.7M | -79.8M | -47.6M | -41.6M | -38.9M |
| EPS | -49 | -34 | -12 | -2.36 | -1.34 | -1.24 |
| Balance Sheet | ||||||
| Total Assets | 66.7M | 49.5M | 57.7M | 78.6M | 76.5M | 66.6M |
| Total Liabilities | 45.6M | 41.6M | 14.2M | 12.9M | 10.0M | 22.1M |
| Shareholders' Equity | 21.8M | 9.22M | 45.8M | 68.7M | 69.7M | 47.8M |
| Cash & Short-term Investments | 1.71M | 10.4M | 15.3M | 22.5M | 21.5M | 3.87M |
| Cash Flow | ||||||
| Capital Expenditure | 555K | 562K | 5.50M | 6.63M | 2.80M | 11.4M |
| Free Cash Flow | -66.7M | -82.1M | -72.0M | -63.9M | -36.0M | -35.3M |
| Ratios | ||||||
| ROE | -291.9% | -766.6% | -174.3% | -69.3% | -59.7% | -81.3% |
| ROA | -95.3% | -142.7% | -138.2% | -60.6% | -54.4% | -58.5% |
| Net Profit Margin | -2,833.6% | -1,127.3% | -964.5% | -253.5% | -238.0% | -217.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Clinical Laserthermia Systems AB (publ) dividends
Clinical Laserthermia Systems AB (publ) has not paid dividends in the last 5 fiscal years.
Last stock split: 1:200 on Apr 25, 2024.
Who owns Clinical Laserthermia Systems AB (publ)
- Insiders 8.85%
- Institutions 9.47%
- Public & others 81.68%
- Shares outstanding 48.5M
- Free float 26.1M
Clinical Laserthermia Systems AB (publ) company profile
- Company name
- Clinical Laserthermia Systems AB (publ)
- Ticker
- LS60.F
- ISIN
- SE0022049920
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Medical Devices
- Employees
- 13
- Fiscal year end
- December
- Address
- Building 405, Lund, Sweden, 223 81
- Phone
- 46 46 15 21 00
- Website
- clinicallaser.se
About Clinical Laserthermia Systems AB (publ)
Clinical Laserthermia Systems AB (publ) engages in the development of treatment tools for diseased tissue under the TRANBERG brand in Sweden. It offers TRANBERG, a thermal therapy system designed to deliver laser energy to heat the target tissue. The company also provides mobile laser unit, a controlling component with a wavelength of 1064 nanometers that provides multiple options to control treatment. In addition, it offers various gauge laser applicators and introducers, as well as provides temperature and treatment monitoring devices. The company has a strategic partnership with ClearPoint Neuro Inc. for the development of ClearPoint Prism, a Neuro Laser Therapy System. Clinical Laserthermia Systems AB (publ) was incorporated in 2006 and is headquartered in Lund, Sweden.
Clinical Laserthermia Systems AB (publ) management
5- Mr. Dan Johansson MogrenChief Executive Officer · born 1964
- Prof. Katarina LundqvistChief Financial Officer · born 1972
- Mr. Jimmy JohanssonChief Operating Officer · born 1981
- Ms. Cristina PantaleoneChief Technical Officer · born 1987
- Verena KnappeC.P.O